The addition of short-course androgen-deprivation therapy (ADT) to upfront radiotherapy is the standard-of-care approach for patients with intermediate-risk or high-risk localized prostate cancer; however, the role of ADT in those receiving radiotherapy after radical prostatectomy is unclear. Now, results from the phase III RADICALS-HD trial provide insights that could help to guide treatment decision making.

In this trial, patients eligible for radiotherapy at any time after radical prostatectomy were randomly allocated (1:1:1) to radiotherapy alone or with ADT (LHRH agonist or bicalutamide) for either 6 months or 24 months (short or long course, respectively). Participant sites were encouraged to perform three-way allocation of patients, although two-way allocation was also permitted to facilitate recruitment. In 2010, the trial was repowered for two separate comparisons, both with metastasis-free survival (MFS) as the primary end point. The median follow-up duration was 9 years.

在前期放疗中加入短程雄激素剥夺治疗 （ADT） 是中危或高危局限性前列腺癌患者的标准治疗方法;然而，ADT 在根治性前列腺切除术后接受放疗的患者中的作用尚不清楚。现在，III 期 RADICALS-HD 试验的结果提供了有助于指导治疗决策的见解。

在该试验中，根治性前列腺切除术后任何时间符合放疗条件的患者被随机分配 （1：1：1） 接受单独放疗或联合 ADT （LHRH 激动剂或比卡鲁胺） 治疗 6 个月或 24 个月 （分别为短期或长期）。鼓励参与者站点对患者进行三向分配，尽管也允许双向分配以促进招募。2010 年，该试验被重新驱动以进行两项独立的比较，均以无转移生存期 （MFS） 作为主要终点。中位随访时间为 9 年。